• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定 NVP-TNKS656:利用结构-效关系生成高效、选择性和口服活性的 tankyrase 抑制剂。

Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.

机构信息

Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

出版信息

J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13.

DOI:10.1021/jm400807n
PMID:23844574
Abstract

Tankyrase 1 and 2 have been shown to be redundant, druggable nodes in the Wnt pathway. As such, there has been intense interest in developing agents suitable for modulating the Wnt pathway in vivo by targeting this enzyme pair. By utilizing a combination of structure-based design and LipE-based structure efficiency relationships, the core of XAV939 was optimized into a more stable, more efficient, but less potent dihydropyran motif 7. This core was combined with elements of screening hits 2, 19, and 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders. NVP-TNKS656 (43) was identified as an orally active antagonist of Wnt pathway activity in the MMTV-Wnt1 mouse xenograft model. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in vivo validation studies.

摘要

Tankyrase 1 和 2 已被证明在 Wnt 通路中是冗余的、可成药的节点。因此,人们强烈关注开发合适的药物来通过靶向该酶对在体内调节 Wnt 通路。通过结合基于结构的设计和基于 LipE 的结构效率关系,XAV939 的核心被优化为更稳定、更高效但效力较低的二氢吡喃基 motif 7。该核心与筛选命中化合物 2、19 和 33 的部分元素结合,产生了高度有效、选择性的 tankyrase 抑制剂,是新型三口袋结合物。NVP-TNKS656(43)被鉴定为 MMTV-Wnt1 小鼠异种移植模型中 Wnt 通路活性的口服拮抗剂。具有驱动力为焓的结合热力学特征、非常有利的物理化学性质和高亲脂效率,NVP-TNKS656 是一种新型的 tankyrase 抑制剂,非常适合进一步的体内验证研究。

相似文献

1
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.鉴定 NVP-TNKS656:利用结构-效关系生成高效、选择性和口服活性的 tankyrase 抑制剂。
J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13.
2
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.开发新型双重结合物作为有效、选择性和口服生物利用度的 Tankyrase 抑制剂。
J Med Chem. 2013 Dec 27;56(24):10003-15. doi: 10.1021/jm401317z. Epub 2013 Dec 11.
3
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.发现新型诱导口袋结合恶唑烷酮类作为有效、选择性和口服生物利用度的 tankyrase 抑制剂。
J Med Chem. 2013 Jun 13;56(11):4320-42. doi: 10.1021/jm4000038. Epub 2013 May 23.
4
Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.发现一类新型的 Tankyrase 抑制剂,它们可以同时结合烟酰胺口袋和诱导口袋。
J Med Chem. 2013 Feb 14;56(3):1341-5. doi: 10.1021/jm301607v. Epub 2013 Jan 23.
5
Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.发现并优化 2-芳基喹唑啉-4-酮类化合物,得到一个强效和选择性的 Tankyrase 抑制剂,调节 Wnt 通路活性。
J Med Chem. 2019 Sep 12;62(17):7897-7909. doi: 10.1021/acs.jmedchem.9b00656. Epub 2019 Aug 20.
6
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.一种新型 Tankyrase 小分子抑制剂抑制 APC 突变驱动的结直肠肿瘤生长。
Cancer Res. 2013 May 15;73(10):3132-44. doi: 10.1158/0008-5472.CAN-12-4562. Epub 2013 Mar 28.
7
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases.作为新型烟酰胺同系物的[1,2,4]三唑-3-基胺抑制端锚聚合酶的结构-效关系。
J Med Chem. 2013 Sep 12;56(17):7049-59. doi: 10.1021/jm400826j. Epub 2013 Aug 14.
8
para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.对取代的 2-苯基-3,4-二氢喹唑啉-4-酮作为有效的和选择性的 tankyrase 抑制剂。
ChemMedChem. 2013 Dec;8(12):1978-85. doi: 10.1002/cmdc.201300337. Epub 2013 Oct 15.
9
Screening and structural analysis of flavones inhibiting tankyrases.筛选和结构分析抑制端锚聚合酶的类黄酮。
J Med Chem. 2013 May 9;56(9):3507-17. doi: 10.1021/jm3018783. Epub 2013 Apr 24.
10
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.基于结构的 G007-LK 的作用机制和 SAR 研究,一种先导化合物,1,2,4-三唑类靶向 tankyrase 1/2 的抑制剂。
J Med Chem. 2013 Apr 11;56(7):3012-23. doi: 10.1021/jm4000566. Epub 2013 Mar 29.

引用本文的文献

1
Synthesis of Novel Derivatives of 4,6-Diarylpyrimidines and Dihydro-Pyrimidin-4-one and Screening of Their Anticancer Activity.4,6-二芳基嘧啶和二氢嘧啶-4-酮的新型衍生物的合成及其抗癌活性筛选
Curr Org Synth. 2025;22(4):556-567. doi: 10.2174/0115701794356958241024082646.
2
Enantioselective [5 + 1] cycloaddition of sulfur ylides and vinylethylene carbonates synergistic palladium/chiral phosphonic acid catalysis.硫叶立德与碳酸乙烯基亚乙酯的对映选择性[5 + 1]环加成反应:协同钯/手性膦酸催化
Chem Sci. 2025 Apr 8;16(18):8108-8113. doi: 10.1039/d5sc01050k. eCollection 2025 May 7.
3
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.
双位点端锚聚合酶抑制剂的解构为结合能提供了见解,并为配体优化指明了关键热点。
J Med Chem. 2025 Apr 10;68(7):7263-7279. doi: 10.1021/acs.jmedchem.4c02845. Epub 2025 Mar 25.
4
Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies.靶向聚(ADP-核糖)化依赖性泛素化信号通路用于癌症治疗
Biomolecules. 2025 Feb 7;15(2):237. doi: 10.3390/biom15020237.
5
Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader.通过选择性PARP1降解剂在保持活性抑制的同时最小化DNA捕获。
Cell Death Dis. 2024 Dec 18;15(12):898. doi: 10.1038/s41419-024-07277-2.
6
Tankyrase inhibition promotes endocrine commitment of hPSC-derived pancreatic progenitors.端锚聚合酶抑制促进人多能干细胞来源的胰腺祖细胞的内分泌分化。
Nat Commun. 2024 Oct 9;15(1):8754. doi: 10.1038/s41467-024-53068-w.
7
The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review.苯甲酰哌啶片段作为药物化学中的优势结构:全面综述。
Molecules. 2024 Apr 23;29(9):1930. doi: 10.3390/molecules29091930.
8
A New Wave of Targeting 'Undruggable' Wnt Signaling for Cancer Therapy: Challenges and Opportunities.针对癌症治疗的“不可成药” Wnt 信号的新一波靶向治疗:挑战与机遇。
Cells. 2023 Apr 8;12(8):1110. doi: 10.3390/cells12081110.
9
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models.Tankyrase 抑制剂 OM-153 在小鼠模型中表现出抗肿瘤疗效和治疗窗口。
Cancer Res Commun. 2022 Apr 20;2(4):233-245. doi: 10.1158/2767-9764.CRC-22-0027. eCollection 2022 Apr.
10
PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1.PARP1pred:一个用于筛选针对DNA修复酶PARP-1的抑制剂生物活性的网络服务器。
EXCLI J. 2023 Jan 5;22:84-107. doi: 10.17179/excli2022-5602. eCollection 2023.